Barr, FDA In Discussions On Trigger For Generic Prozac Exclusivity
• By The Pink Sheet
Barr's 180 days of Waxman/Hatch exclusivity for generic fluoxetine could depend on FDA's determination of whether a brand name company's pediatric exclusivity supercedes generic exclusivity, Barr told analysts during its quarterly conference call Oct. 24.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
